MX2022016454A - Compuestos macrociclicos y metodos de uso de los mismos. - Google Patents

Compuestos macrociclicos y metodos de uso de los mismos.

Info

Publication number
MX2022016454A
MX2022016454A MX2022016454A MX2022016454A MX2022016454A MX 2022016454 A MX2022016454 A MX 2022016454A MX 2022016454 A MX2022016454 A MX 2022016454A MX 2022016454 A MX2022016454 A MX 2022016454A MX 2022016454 A MX2022016454 A MX 2022016454A
Authority
MX
Mexico
Prior art keywords
macrocyclic
methods
eulbm
binding motif
macrocyclic compounds
Prior art date
Application number
MX2022016454A
Other languages
English (en)
Inventor
Hao Wu
Jakob Fuhrmann
Wayne Fairbrother
Jeremy Murray
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022016454A publication Critical patent/MX2022016454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen compuestos macrocíclicos que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y al menos un aminoácido, y métodos para preparar y usar tales EULBM macrocíclicos para el tratamiento del cáncer o de una condición fibrótica. También se proveen inductores químicos heterobifuncionales macrocíclicos de degradación (CIDE) que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y un motivo de unión a la proteína diana (TPBM) unidos por al menos un aminoácido.
MX2022016454A 2020-06-23 2021-06-22 Compuestos macrociclicos y metodos de uso de los mismos. MX2022016454A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043071P 2020-06-23 2020-06-23
PCT/US2021/038503 WO2021262731A2 (en) 2020-06-23 2021-06-22 Macrocyclic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022016454A true MX2022016454A (es) 2023-03-06

Family

ID=77207221

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016454A MX2022016454A (es) 2020-06-23 2021-06-22 Compuestos macrociclicos y metodos de uso de los mismos.

Country Status (17)

Country Link
US (2) US12187816B2 (es)
EP (1) EP4168121A2 (es)
JP (1) JP2023532233A (es)
KR (1) KR20230026461A (es)
CN (1) CN115702026A (es)
AR (1) AR122707A1 (es)
AU (1) AU2021297799A1 (es)
BR (1) BR112022026364A2 (es)
CA (1) CA3185149A1 (es)
CL (4) CL2022003643A1 (es)
CO (1) CO2022018532A2 (es)
CR (1) CR20220658A (es)
IL (1) IL299163A (es)
MX (1) MX2022016454A (es)
PE (1) PE20230617A1 (es)
TW (1) TWI906316B (es)
WO (1) WO2021262731A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260001914A1 (en) * 2022-07-21 2026-01-01 Merck Sharp & Dohme Llc Macrocyclic peptides targeting kras
ES3041442T3 (en) * 2022-12-27 2025-11-12 Evonik Oxeno Gmbh & Co Kg Process for the preparation of a phosphoramidite and its further conversion to monophosphite
KR20260028831A (ko) * 2023-06-26 2026-03-04 알부넥스트 엘엘씨 Glp-1/gip/글루카곤 수용체를 활성화시키는 알부민 결합 거대분자 삼중효능제 및 이를 위한 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144233A (en) 1977-02-16 1979-03-13 The Dow Chemical Company Method for preparing benzo-(1,3,4)-benzotriazepines
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
ES2233070T3 (es) * 1998-08-20 2005-06-01 ELI LILLY & COMPANY Sintesis de analogos peptidicos ciclicos modificados en el anillo.
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
AU2010314395B2 (en) 2009-11-05 2015-04-09 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN103119160B (zh) 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
JP6532599B2 (ja) 2015-09-02 2019-06-19 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
EP3675878A4 (en) * 2017-10-02 2021-06-16 Fred Hutchinson Cancer Research Center LUTEINIZING HORMONE RECEPTOR BINDERS AND LUTEINIZING HORMONAGONISTS FOR IDENTIFICATION, EXPANSION, ABLATION AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS
EP3724216A1 (en) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2019162974A1 (en) * 2018-02-23 2019-08-29 Ulisse Biomed S.R.L. Method to diagnose cancer progression based on prokaryotic biomarkers and molecules for use in the treatment of cancer progression

Also Published As

Publication number Publication date
TW202219056A (zh) 2022-05-16
CL2025000750A1 (es) 2025-07-04
CO2022018532A2 (es) 2022-12-30
IL299163A (en) 2023-02-01
US12187816B2 (en) 2025-01-07
AU2021297799A1 (en) 2022-12-22
CL2022003643A1 (es) 2023-05-26
WO2021262731A3 (en) 2022-02-24
CL2023002555A1 (es) 2024-01-26
AR122707A1 (es) 2022-09-28
CN115702026A (zh) 2023-02-14
JP2023532233A (ja) 2023-07-27
KR20230026461A (ko) 2023-02-24
EP4168121A2 (en) 2023-04-26
CA3185149A1 (en) 2021-12-30
BR112022026364A2 (pt) 2023-01-17
US20250129125A1 (en) 2025-04-24
WO2021262731A2 (en) 2021-12-30
CL2025000748A1 (es) 2025-07-04
US20220106361A1 (en) 2022-04-07
TWI906316B (zh) 2025-12-01
CR20220658A (es) 2023-04-26
PE20230617A1 (es) 2023-04-14

Similar Documents

Publication Publication Date Title
CL2023002555A1 (es) Compuestos macrocíclicos y métodos de uso de los mismos (divisional ).
BR112021017583A2 (pt) Compostos, composições e métodos para o tratamento de doença
EA202191730A1 (ru) Ингибиторы kif18a
CO2020009625A2 (es) Inhibidor de fap
CL2021003419A1 (es) Agonistas del receptor del péptido-1 similar al glucagón
ECSP20021323A (es) Proteínas de unión condicionalmente activadas restringidas
ES2542853T3 (es) Método para tratar miastenia grave
BR112021020023A2 (pt) Ligantes de conjugação melhorados
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
PY2263012A (es) Composiciones para el control fúngico y métodos relacionados
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112021019196A2 (pt) Composições e métodos compreendendo um rna guia de ttr e um polinucleotídeo codificando um agente de ligação de dna guiado por rna
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
AU2019310335A8 (en) Methods of treating cancer with PI3K inhibitor, GDC-0077
CL2021001739A1 (es) Inhibidores de la proteína de activación de fibroblastos.
MX2024002261A (es) Molecula de union de fap/cd40 y uso medicinal de la misma.
BR112022012278A2 (pt) Combinações
MX2024002411A (es) Antagonista biológico que contiene anillos aromáticos, y método para su preparación y su uso.
MX2022007626A (es) Combinaciones.
BR112022012280A2 (pt) Combinações
MX2022007623A (es) Combinaciones.
WO2024077023A3 (en) Cereblon-recruiting bcl-xl/bcl-2 dual degraders
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.